Ctrough is the observed amivantamab serum concentration immediately prior to the next drug administration.

An adverse event is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the drug. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.

Number of participants with DLT will be assessed.

Number of participants with clinical laboratory (hematology, clinical chemistry, and urinalysis) abnormalities will be assessed.